Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever

Summary

This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).

Timeline

Start

2001-07

Primary completion

2002-11

Completion

2002-11

Publications

• Results Chuansumrit A, Wangruangsatid S, Lektrakul Y, Chua MN, Zeta Capeding MR, Bech OM; Dengue Study Group. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005 Nov;16(8):549-55. doi: 10.1097/01.mbc.0000186837.78432.2f.

Drugs

Indications